HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
NovaBay Pharmaceuticals, Inc. (NBY)
1.14  -0.19  (-14.29%) 08-10 01:34
Open: 1.1 High: 1.17
Pre.close: 1.33 Low: 1.08
Volume: 4,349,150 Ave vol: 5,450,885
52w High: 1.94 52w Low: 0.24
MA(50): 1.222 MA(200): 0.87
EPS: -0.361 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novabay.com
Market Cap (M): 38
Shares Out (M): 33
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Technical analysis
Overall: Sell
MA: Bullish MACD: Bearish
KDJ: Bearish RSI: Bearish
Target 1: 1.88 Target 2: 2.27
Resist 1: 1.61 Resist 2: 1.94
Support 1: 1.07 Support 2: 0.89
Company key metrics
Revenue per Share: 0.3049
Net Income per Share: -0.4463
Cash per Share: 0.3205
Book Value per Share: 0.045
Price to Sales: 2.0005
Price to Book Value: 13.5673
Earnings Yield: -0.7316
Dividend Yield: 0
Debt to Equity: 10.5313
Debt to Assets: 0.9133
Financial analysis
Price to Book Value: Outperform
Return on Assets: Underperform
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Outperform
Stock Charts
Headline news
Sun, 09 Aug 2020
NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2020 Results - Earnings Call Transcript - Seeking Alpha

Fri, 07 Aug 2020
Is NovaBay Pharmaceuticals, Inc. (NBY) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Thu, 06 Aug 2020
NovaBay Pharmaceuticals Reports Second Quarter 2020 Financial Results - Yahoo Finance

Thu, 06 Aug 2020
Are Shares Of NovaBay Pharmaceuticals, Inc. (NBY) Really Worth? - Invest Million

Tue, 04 Aug 2020
Should You Buy NovaBay Pharmaceuticals, Inc. (NBY) Stock on Tuesday? - InvestorsObserver

Mon, 03 Aug 2020
Gear up for the change! NovaBay Pharmaceuticals Inc. (NBY) has hit the volume of 1392532 - The InvestChronicle

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.